Riding the Omicron BA.5 wave: improved humoral response after vaccination with bivalent Omicron BA.4-5-adapted mRNA SARS-CoV-2 vaccine in chronic hemodialysis patients

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Deutsch

Notes: Frankfurt am Main, Johann Wolfgang Goethe-Universität, Dissertation, 2025

Keyword: Impfung
COVID-19
SARS-CoV-2
Impfstoff

Event: Veröffentlichung

(where): Frankfurt am Main

(who): Universitätsbibliothek Johann Christian Senckenberg

(when): 2025

Creator: Ovčar, Eugen

Contributor: Hauser, Ingeborg A.
Groot, Kirsten de
Munschauer, Mathias

DOI: 10.21248/gups.89765

URN: urn:nbn:de:hebis:30:3-897654

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:30 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Ovčar, Eugen
Hauser, Ingeborg A.
Groot, Kirsten de
Munschauer, Mathias
Universitätsbibliothek Johann Christian Senckenberg

Time of origin

2025

Other Objects (12)

Riding the Omicron BA.5 wave: improved humoral response after vaccination with bivalent Omicron BA.4-5-adapted mRNA SARS-CoV-2 vaccine in chronic hemodialysis patients

Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron

Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage

Technetium abundance in Omicron Ceti

Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants

Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia

Riding the Omicron BA.5 wave: improved humoral response after vaccination with bivalent Omicron BA.4-5-adapted mRNA SARS-CoV-2 vaccine in chronic hemodialysis patients

Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron

Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage

Technetium abundance in Omicron Ceti

Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants

Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia

Riding the Omicron BA.5 wave: improved humoral response after vaccination with bivalent Omicron BA.4-5-adapted mRNA SARS-CoV-2 vaccine in chronic hemodialysis patients

Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron

Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage

Technetium abundance in Omicron Ceti

Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants

Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Riding the Omicron BA.5 wave: improved humoral response after vaccination with bivalent Omicron BA.4-5-adapted mRNA SARS-CoV-2 vaccine in chronic hemodialysis patients

Object Details

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Time of origin

Other Objects (12)

Riding the Omicron BA.5 wave: improved humoral response after vaccination with bivalent Omicron BA.4-5-adapted mRNA SARS-CoV-2 vaccine in chronic hemodialysis patients

Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron

Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage

Technetium abundance in Omicron Ceti

Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants

Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia

Riding the Omicron BA.5 wave: improved humoral response after vaccination with bivalent Omicron BA.4-5-adapted mRNA SARS-CoV-2 vaccine in chronic hemodialysis patients

Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron

Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage

Technetium abundance in Omicron Ceti

Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants

Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia

Riding the Omicron BA.5 wave: improved humoral response after vaccination with bivalent Omicron BA.4-5-adapted mRNA SARS-CoV-2 vaccine in chronic hemodialysis patients

Omicron-specific and bivalent omicron-containing vaccine candidates elicit potent virus neutralisation in the animal model

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine

Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19

Neutralization against Omicron sublineages (BA.2/BA.5/BQ.1.1/XBB/XBB.1.5) in bivalent BNT162b2-vaccinated HCWs with or without risk factors, or following BT infection with Omicron

Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage

Technetium abundance in Omicron Ceti

Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants

Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia

Related objects

Reset password